keyword
MENU ▼
Read by QxMD icon Read
search

Bisphosphonates IV

keyword
https://www.readbyqxmd.com/read/28935593/factors-affecting-peri-implant-fracture-following-locking-plate-for-osteoporotic-distal-femur-fractures
#1
Ki-Chul Park, Seung-Jae Lim, Young Sik Song, Kyu-Tae Hwang
INTRODUCTION: The purpose of this study is to evaluate the outcomes and to analyze the risk factors for the occurrence of peri-implant fracture after treatment of osteoporotic distal femoral fracturesusing a locking plate. HYPOTHESIS: Risk factors affecting peri-implant fracture exist after locking plate fixation in osteoporotic distal femur fracture. MATERIALS AND METHODS: Eighty nine(88 patients) with osteoporotic distal femoral fractures were evaluated between January2006 and January2014...
September 18, 2017: Orthopaedics & Traumatology, Surgery & Research: OTSR
https://www.readbyqxmd.com/read/28902456/safety-and-efficacy-of-hydroxyapatite-scaffold-in-the-prevention-of-jaw-osteonecrosis-in-vivo
#2
Adriana Duarte de Almeida, Fernanda Gomes Leite, Marco Vinícius Chaud, Márcia de Araújo Rebelo, Liliane Cristine Ferreira de Souza Borges, Fabia Judice Marques Viroel, Alessandre Hataka, Denise Grotto
Two scaffolds of chitosan/sodium alginate/hydroxyapatite (Ch/NaAlg/Hap) 1:1:0.2 and 1:1:0.6 were evaluated in the prevention of bisphosphonate-induced jaw osteonecrosis. Two groups of rats (n = 24, according to the euthanasia time: 15 or 30 days after the last Zoledronic acid (ZA) administration) were subdivided in four subgroups (n = 6): I - Control (saline + teeth extraction); II - ZA 0.6 mg/kg + teeth extraction; III - ZA + teeth extraction + scaffold 1:1:0.2; IV - ZA + teeth extraction + scaffold 1:1:0...
September 13, 2017: Journal of Biomedical Materials Research. Part B, Applied Biomaterials
https://www.readbyqxmd.com/read/28869827/effects-of-dexamethasone-and-nimesulide-on-bisphosphonate-related-osteonecrosis-of-the-jaw-an-experimental-study
#3
Camila Carvalho de Oliveira, Paulo Goberlânio de Barros Silva, Antonio Ernando Carlos Ferreira, Romélia Pinheiro Gonçalves, Fabrício Bitu de Sousa, Mário Rogério Lima Mota, Ana Paula Negreiros Nunes Alves
OBJECTIVE: To evaluate the effects of dexamethasone (DEX) and nimesulide (NIM) on Bisphosphonate-related Osteonecrosis of the Jaw (BRONJ) in rats. DESIGN: BRONJ was induced by zoledronic acid (ZA) infusion (0.2mg/kg) in Wistar rats (n=8), followed by extraction of the left lower first molar (BRONJ groups). Control groups (n=40) received saline (IV). For eight weeks, DEX (0.04, 0.4, 4mg/kg) or saline (SAL) were administered by gavage 24h before each infusion of ZA or saline (IV), or NIM (10...
August 30, 2017: Archives of Oral Biology
https://www.readbyqxmd.com/read/28856724/sirt1-herc4-locus-associated-with-bisphosphonate-induced-osteonecrosis-of-the-jaw-an-exome-wide-association-analysis
#4
Guang Yang, Issam Hamadeh, Joseph Katz, Alberto Riva, Peter Lakatos, Bernadett Balla, Janos Kosa, Mihaly Vaszilko, Gian Andrea Pelliccioni, Noa Davis, Taimour Y Langaee, Jan S Moreb, Yan Gong
Osteonecrosis of jaw (ONJ) is a rare but serious adverse drug side effect, mainly associated with the use of intravenous (IV) bisphosphonates (BPs). The purpose of this study was to identify genetic variants associated with ONJ in patients of European ancestry treated with IV BPs using a whole-exome sequencing (WES). The WES phase 1 included 44 multiple myeloma patients (22 ONJ cases and 22 controls) and WES phase 2 included 17 ONJ patients with solid tumors. Multivariable logistic regression analysis was performed to estimate the odds ratios (ORs) and 95% confidence intervals (CI) adjusting for age, gender and principal components for ancestry...
August 30, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28717700/prostate-cancer-burden-at-the-uganda-cancer-institute
#5
Fred Okuku, Jackson Orem, George Holoya, Chris De Boer, Cheryl L Thompson, Matthew M Cooney
PURPOSE: In Uganda, the incidence of prostate cancer is increasing at a rate of 5.2% annually. Data describing presentation and outcomes for patients with prostate cancer are lacking. METHODS: A retrospective review of medical records for men with histologically confirmed prostate cancer at the Uganda Cancer Institute (UCI) from January 1 to December 17, 2012, was performed. RESULTS: Our sample included 182 men whose mean age was 69.5 years (standard deviation, 9...
August 2016: Journal of Global Oncology
https://www.readbyqxmd.com/read/28692452/acetabular-protrusio-in-patients-with-osteogenesis-imperfecta-risk-factors-and-progression
#6
Junho Ahn, Erin Carter, Cathleen L Raggio, Daniel W Green
BACKGROUND: Osteogenesis imperfecta (OI) is a genetic disorder commonly associated with osteopenia, osteoporosis, bone fractures, bone deformities, and other clinical features. A frequent radiologic finding with OI is acetabular protrusio (AP). We hypothesized that AP develops in patients with OI over time. In addition, we hypothesized that AP also develops in patients with OI without radiographic evidence of AP on initial examination. METHODS: Medical records and radiographs of 55 patients (109 hips) diagnosed with OI evaluated at our institution were retrospectively reviewed...
July 7, 2017: Journal of Pediatric Orthopedics
https://www.readbyqxmd.com/read/28656488/the-role-of-monocyte-subpopulations-in-vascular-injury-following-partial-and-transient-depletion
#7
Etty Grad, Ksenia Zolotarevsky, Haim D Danenberg, Mirjam M Nordling-David, Dikla Gutman, Gershon Golomb
The innate immunity system plays a critical role in vascular repair and restenosis development. Liposomes encapsulating bisphosphonates (LipBPs), but not free BPs, suppress neointima formation following vascular injury mediated in part by monocytes. The objective of this study was to elucidate the role of monocyte subpopulations on vascular healing following LipBP treatment. The potency- and dose-dependent treatment effect of clodronate (CLOD) and alendronate (ALN) liposomes on restenosis inhibition, total monocyte depletion, and monocytes subpopulation was studied...
June 27, 2017: Drug Delivery and Translational Research
https://www.readbyqxmd.com/read/28567535/immune-mediated-syndromes-following-intravenous-bisphosphonate-therapy
#8
Noa Markovits, Ronen Loebstein, Ilan Bank
OBJECTIVES: Intravenous (IV) infusion of aminobisphosphonates (ABP) induces cytokine release by peripheral blood Vγ9δ2 T cells, resulting in an immediate short-term inflammatory response in up to 50% of patients. We evaluated possible long-term pro-inflammatory effects of IV ABP. METHODS: Retrospective case-series study from one rheumatology specialist's clinic. 2261 electronic charts were reviewed for administration of 'zoledronate' or different brand names of zoledronic acid, and relevant clinical data was retrieved for patients who had received the infusion...
May 31, 2017: Inflammopharmacology
https://www.readbyqxmd.com/read/28548288/hypermineralization-and-high-osteocyte-lacunar-density-in-osteogenesis-imperfecta-type-v-bone-indicate-exuberant-primary-bone-formation
#9
Stéphane Blouin, Nadja Fratzl-Zelman, Francis H Glorieux, Paul Roschger, Klaus Klaushofer, Joan C Marini, Frank Rauch
In contrast to "classical" forms of osteogenesis imperfecta (OI) types I to IV, caused by a mutation in COL1A1/A2, OI type V is due to a gain-of-function mutation in the IFITM5 gene, encoding the interferon-induced transmembrane protein 5, or bone-restricted interferon-inducible transmembrane (IFITM)-like protein (BRIL). Its phenotype distinctly differs from OI types I to IV by absence of blue sclerae and dentinogenesis imperfecta, by the occurrence of ossification disorders such as hyperplastic callus and forearm interosseous membrane ossification...
September 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28461254/combination-sclerostin-antibody-and-zoledronic-acid-treatment-outperforms-either-treatment-alone-in-a-mouse-model-of-osteogenesis-imperfecta
#10
David G Little, Lauren Peacock, Kathy Mikulec, Michaela Kneissel, Ina Kramer, Tegan L Cheng, Aaron Schindeler, Craig Munns
In this study, we examined the therapeutic potential of anti-Sclerostin Antibody (Scl-Ab) and bisphosphonate treatments for the bone fragility disorder Osteogenesis Imperfecta (OI). Mice with the Amish OI mutation (Col1a2 G610C mice) and control wild type littermates (WT) were treated from week 5 to week 9 of life with (1) saline (control), (2) zoledronic acid given 0.025mg/kg s.c. weekly (ZA), (3) Scl-Ab given 50mg/kg IV weekly (Scl-Ab), or (4) a combination of both (Scl-Ab/ZA). Functional outcomes were prioritized and included bone mineral density (BMD), bone microarchitecture, long bone bending strength, and vertebral compression strength...
April 29, 2017: Bone
https://www.readbyqxmd.com/read/28407986/intravenous-bisphosphonate-therapy-does-not-thicken-cementum-or-change-periodontal-ligaments-of-cancer-patients
#11
Mariana de Pauli Paglioni, Wagner Gomes Silva, Juliana Pereira, César Augusto Migliorati, Marcio Ajudarte Lopes, Oslei Paes de Almeida, Mario Fernando Goes, Ana Carolina Prado Ribeiro, Thais Bianca Brandão, Alan Roger Santos-Silva
OBJECTIVE: To test the hypothesis that intravenous (IV) bisphosphonate (BP) therapy thickens or alters the micromorphology of cementum and periodontal ligament (PDL) in cancer patients. STUDY DESIGN: Thirty-two teeth extracted from 24 cancer patients and separated into test (patients who have undergone IV BP therapy, n = 16) and control (patients naive to BP therapy, n = 16) groups were studied. Cementum thickness was measured in 3 different areas of the dental root with polarized light microscopy...
May 2017: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
https://www.readbyqxmd.com/read/28337806/the-pharmacological-profile-of-a-novel-highly-potent-bisphosphonate-ox14-1-fluoro-2-imidazo-1-2-%C3%AE-pyridin-3-yl-ethyl-bisphosphonate
#12
Michelle A Lawson, Frank H Ebetino, Adam Mazur, Andrew D Chantry, Julia Paton-Hough, Holly R Evans, Darren Lath, Maria K Tsoumpra, Mark W Lundy, Roy Lm Dobson, Michael Quijano, Aaron A Kwaasi, James E Dunford, Xuchen Duan, James T Triffitt, Gwyn Jeans, R Graham G Russell
Bisphosphonates are widely used in the treatment of clinical disorders characterized by increased bone resorption, including osteoporosis, Paget's disease, and the skeletal complications of malignancy. The antiresorptive potency of the nitrogen-containing bisphosphonates on bone in vivo is now recognized to depend upon two key properties, namely mineral binding affinity and inhibitory activity on farnesyl pyrophosphate synthase (FPPS), and these properties vary independently of each other in individual bisphosphonates...
March 24, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28299378/factors-associated-with-acute-phase-response-of-bisphosphonate-na%C3%A3-ve-or-pretreated-women-with-osteoporosis-receiving-an-intravenous-first-dose-of-zoledronate-or-ibandronate
#13
A W Popp, R Senn, I Curkovic, C Senn, H Buffat, P F Popp, K Lippuner
A first intravenous dose of bisphosphonates may be associated with an acute-phase response (APR). In bisphosphonate-naïve women with postmenopausal osteoporosis, the characteristics and frequency of APR may differ by compound. Prior bisphosphonate exposure was predictive of APR risk and severity. INTRODUCTION: Intravenous (IV) administration of bisphosphonates (BP), such as zoledronate (ZOL) and ibandronate (IBN), may be associated with an APR. The characteristics of APR may differ by compound...
June 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28179107/pro-inflammatory-immune-to-brain-signaling-is-involved-in-neuroendocrine-responses-to-acute-emotional-stress
#14
Jordi Serrats, Jan-Sebastian Grigoleit, Elena Alvarez-Salas, Paul E Sawchenko
Activation of the hypothalamo-pituitary-adrenal (HPA) axis by inflammatory stressors (e.g., bacterial lipopolysaccharide) is thought to involve vascular transduction of circulating cytokines, with perivascular macrophages (PVMs) along with endothelia, effecting activation of HPA control circuitry via inducible (cyclooxygenase-2- or COX-2-dependent) prostaglandin synthesis. To test the stressor-specificity of this mechanism, we examined whether ablation of PVMs or pharmacologic blockade of COX activity affected HPA responses to a representative emotional stressor, restraint...
February 4, 2017: Brain, Behavior, and Immunity
https://www.readbyqxmd.com/read/28101496/medication-related-osteonecrosis-of-the-jaw-a-preliminary-retrospective-study-of-130-patients-with-multiple-myeloma
#15
Woo-Sung Choi, Jae-Il Lee, Hyun-Joong Yoon, Chang-Ki Min, Sang-Hwa Lee
BACKGROUND: Multiple myeloma (MM) is characterized by a neoplastic proliferation of plasma cells primarily in the bone marrow. Bisphosphonates (BP) are used as supportive therapy in the management of MM. This study aimed to analyze the incidence, risk factors, and clinical outcomes of medication-related necrosis of the jaw (MRONJ) in MM patients. METHODS: One hundred thirty MM patients who had previous dental evaluations were retrospectively reviewed. Based on several findings, we applied the staging and treatment strategies on MRONJ...
December 2017: Maxillofacial Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/28027521/correlation-between-severe-infection-and-breast-cancer-metastases-in-the-eortc-10994-big-1-00-trial-investigating-innate-immunity-as-a-tumour-suppressor-in%C3%A2-breast-cancer
#16
RANDOMIZED CONTROLLED TRIAL
Nathan Touati, Konstantinos Tryfonidis, Franco Caramia, Hervé Bonnefoi, David Cameron, Leen Slaets, Belinda S Parker, Sherene Loi
BACKGROUND: Breast cancer cells which express an innate immune signature regulated by interferon regulatory factor 7 (IRF7) have reduced metastatic potential. Infections can induce interferon signalling and may activate an anti-tumour immune response. We investigated whether 'severe infection' can be a clinical surrogate of this phenomenon and/or the presence of high levels of the IRF7 signature at diagnosis before neo-adjuvant chemotherapy (NACT) is associated with a reduced distant relapse risk, specifically in bones...
February 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28009615/healing-of-atypical-subtrochanteric-femur-fractures-after-cephalomedullary-nailing-which-factors-predict-union
#17
Jae-Woo Cho, Chang-Wug Oh, Frankie Leung, Ki-Chul Park, Merng Koon Wong, Ernest Kwek, Han-Ju Kim, Jong-Keon Oh
OBJECTIVES: The purpose of this study was to determine the healing rate and time to union of atypical subtrochanteric fractures treated with cephalomedullary nailing. DESIGN: Retrospective review, descriptive, and analytic study. SETTING: Six level 1 trauma centers. PATIENTS/PARTICIPANTS: The study included 42 patients with 48 displaced, atypical, bisphosphonate-associated subtrochanteric femur fractures who underwent surgical intervention...
March 2017: Journal of Orthopaedic Trauma
https://www.readbyqxmd.com/read/27930925/effects-of-green-tea-and-bisphosphonate-association-on-dental-socket-repair-of-rats
#18
Edson Yoshihiro Mada, Alana Claro Cunha Santos, Angelica Cristina Fonseca, Claudia Cristina Biguetti, Fernando Tozze Alves Neves, Patrícia Pinto Saraiva, Mariza Akemi Matsumoto
OBJECTIVES: To evaluate the effects of green tea intake and zoledronic acid intravenous therapy on teeth socket repair. DESIGN: Sixty male albinus Wistar rats were divided into 4 groups: C-Control, intravenous (IV) 0.9% saline solution (SS), GT-1% green tea in drinking water and IV SS, BP-IV zoledronic acid (BP), and BP+GT-IV BP and 1% green tea. 0.035mg/kg of BP was administered every two weeks. After ten weeks, right upper molars were extracted and the green tea started to be offered for GT and BP+GT...
December 5, 2016: Archives of Oral Biology
https://www.readbyqxmd.com/read/27926679/factors-associated-with-increased-healing-time-in-complete-femoral-fractures-after-long-term-bisphosphonate-therapy
#19
Hae-Seong Lim, Chong-Kwan Kim, Youn-Soo Park, Young-Wan Moon, Seung-Jae Lim, Sang-Min Kim
BACKGROUND: The purpose of this study was to analyze factors that affect healing time after operative treatment of complete femoral fractures associated with long-term use of bisphosphonates. In particular, we sought to determine surgically controllable factors related to fracture-healing time. METHODS: Ninety-nine consecutive patients (109 fractures) who had been surgically treated for a complete atypical femoral fracture were enrolled. All patients had a documented history of bisphosphonate therapy at the time of presentation, with an average duration of 7...
December 7, 2016: Journal of Bone and Joint Surgery. American Volume
https://www.readbyqxmd.com/read/27876314/risk-of-jaw-osteonecrosis-after-intravenous-bisphosphonates-in-cancer-patients-and-patients-without-cancer
#20
COMPARATIVE STUDY
James S Goodwin, Jie Zhou, Yong-Fang Kuo, Jacques Baillargeon
OBJECTIVE: To compare the risk of jaw osteonecrosis after intravenous (IV) bisphosphonate administered to patients with cancer vs patients without cancer. PATIENTS AND METHODS: We conducted a retrospective cohort study of a 5% national sample of Medicare patients administered IV bisphosphonate from January 1, 2008, through December 31, 2013, for cancer vs noncancer indications. Probable jaw osteonecrosis was estimated with an algorithm including diagnoses, surgical procedures, and imaging studies...
January 2017: Mayo Clinic Proceedings
keyword
keyword
96435
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"